Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

Yuji Sato, Toshiyoshi Fujiwara, Takashi Mine, Hiroki Shomura, Shigenori Homma, Yoshiaki Maeda, Naoyuki Tokunaga, Yoshihiro Ikeda, Yuki Ishihara, Akira Yamada, Noriaki Tanaka, Kyogo Itoh, Mamoru Harada, Satoru Todo

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m2/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-γ production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m2/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m2/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.

Original languageEnglish
Pages (from-to)1113-1119
Number of pages7
JournalCancer Science
Volume98
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Fluorouracil
Colorectal Neoplasms
Stomach
Vaccination
Peptides
Cytotoxic T-Lymphocytes
titanium silicide
Immunoglobulin G
Neoplasms
Neutropenia
Interferons
Stomach Neoplasms
Oral Administration
Anemia
Blood Cells
Safety
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. / Sato, Yuji; Fujiwara, Toshiyoshi; Mine, Takashi; Shomura, Hiroki; Homma, Shigenori; Maeda, Yoshiaki; Tokunaga, Naoyuki; Ikeda, Yoshihiro; Ishihara, Yuki; Yamada, Akira; Tanaka, Noriaki; Itoh, Kyogo; Harada, Mamoru; Todo, Satoru.

In: Cancer Science, Vol. 98, No. 7, 07.2007, p. 1113-1119.

Research output: Contribution to journalArticle

Sato, Y, Fujiwara, T, Mine, T, Shomura, H, Homma, S, Maeda, Y, Tokunaga, N, Ikeda, Y, Ishihara, Y, Yamada, A, Tanaka, N, Itoh, K, Harada, M & Todo, S 2007, 'Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients', Cancer Science, vol. 98, no. 7, pp. 1113-1119. https://doi.org/10.1111/j.1349-7006.2007.00498.x
Sato, Yuji ; Fujiwara, Toshiyoshi ; Mine, Takashi ; Shomura, Hiroki ; Homma, Shigenori ; Maeda, Yoshiaki ; Tokunaga, Naoyuki ; Ikeda, Yoshihiro ; Ishihara, Yuki ; Yamada, Akira ; Tanaka, Noriaki ; Itoh, Kyogo ; Harada, Mamoru ; Todo, Satoru. / Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. In: Cancer Science. 2007 ; Vol. 98, No. 7. pp. 1113-1119.
@article{36dc008e5df4495aaf84fd398109e5e9,
title = "Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients",
abstract = "The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m2/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-γ production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m2/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m2/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.",
author = "Yuji Sato and Toshiyoshi Fujiwara and Takashi Mine and Hiroki Shomura and Shigenori Homma and Yoshiaki Maeda and Naoyuki Tokunaga and Yoshihiro Ikeda and Yuki Ishihara and Akira Yamada and Noriaki Tanaka and Kyogo Itoh and Mamoru Harada and Satoru Todo",
year = "2007",
month = "7",
doi = "10.1111/j.1349-7006.2007.00498.x",
language = "English",
volume = "98",
pages = "1113--1119",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

AU - Sato, Yuji

AU - Fujiwara, Toshiyoshi

AU - Mine, Takashi

AU - Shomura, Hiroki

AU - Homma, Shigenori

AU - Maeda, Yoshiaki

AU - Tokunaga, Naoyuki

AU - Ikeda, Yoshihiro

AU - Ishihara, Yuki

AU - Yamada, Akira

AU - Tanaka, Noriaki

AU - Itoh, Kyogo

AU - Harada, Mamoru

AU - Todo, Satoru

PY - 2007/7

Y1 - 2007/7

N2 - The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m2/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-γ production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m2/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m2/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.

AB - The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients. Eleven patients (four with gastric cancer and seven with colorectal cancer) who failed to improve by prior TS-1-based chemotherapies were enrolled in this study. Peptides to be administered to patients were determined based on the presence of peptide-specific cytotoxic T lymphocyte (CTL) precursors in peripheral blood mononuclear cells and peptide-specific IgG in the plasma of cancer patients. Patients were vaccinated with peptides (a maximum of four) biweekly in combination with or without three different doses of TS-1 (20, 40 and 80 mg/m2/day). Although grade 3 toxicity, including anemia (one patient) and neutropenia (one patient) were observed, the combination therapy was generally well tolerated. An increase in peptide-specific IgG after the sixth vaccination was observed in the vast majority of patients irrespective of the dose of TS-1 used. In contrast, an increase in peptide-specific interferon-γ production by CTL was most evident in patients who were administered the highest dose of TS-1. Furthermore, in the patients who received 80 mg/m2/day TS-1, CTL-mediated cytotoxicity against cancer cells was maintained at the prevaccination level. These results indicate that administration of the standard dose (80 mg/m2/day) of TS-1 in combination with a personalized peptide vaccination does not necessarily impede immunological responses in cancer patients, and could actually maintain or augment them.

UR - http://www.scopus.com/inward/record.url?scp=34249879033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249879033&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00498.x

DO - 10.1111/j.1349-7006.2007.00498.x

M3 - Article

VL - 98

SP - 1113

EP - 1119

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -